GlassScriptPhysician profile
Luann Harris
NPI 1235134883
$3,382.73
in general payments reported to CMS, 2019-2025
36 companies · $721 in 2025
The $721 reported for 2025 was more than what 83% of Acute Care (Nurse Practitioner) providers received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $94.35 · 2022: $827 · 2023: $845 · 2024: $895 · 2025: $721.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,440 · Education: $21.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,439.98 |
| Education | $21.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $305.28 | 2022-2025 | Imfinzi, Enhertu |
| Incyte Corporation | $265.34 | 2022-2024 | Pemazyre, Jakafi |
| Gilead Sciences, INC. | $249.15 | 2024-2025 | Trodelvy |
| Novartis Pharmaceuticals Corporation | $219.14 | 2023-2025 | |
| Beigene USA, INC. | $203.09 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $190.55 | 2023-2024 | |
| Mirati Therapeutics, INC. | $142.84 | 2023 | Krazati |
| Myovant Sciences INC. | $124.77 | 2022 | |
| Lilly USA, LLC | $124.38 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Genmab U.S., INC. | $121.87 | 2025 | Epkinly |
| Springworks Therapeutics, INC. | $121.80 | 2024 | Ogsiveo |
| E.R. Squibb & Sons, L.L.C. | $120.27 | 2022-2025 | Opdivo |
| Merck Sharp & Dohme LLC | $109.99 | 2024 | Keytruda, Welireg |
| Aveo Pharmaceuticals, INC. | $96.38 | 2024 | |
| Puma Biotechnology, INC. | $94.35 | 2021 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $78.99 | 2023-2024 | |
| Daiichi Sankyo INC. | $78.68 | 2023-2025 | Enhertu |
| Stemline Therapeutics INC. | $71.45 | 2023-2024 | Orserdu, Elzonris |
| Karyopharm Therapeutics INC. | $70.55 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $70.03 | 2022 | |
| Blueprint Medicines Corporation | $69.75 | 2023 | Ayvakit |
| Abbvie INC. | $68.86 | 2025 | |
| Pfizer INC. | $51.89 | 2022-2024 | |
| Seagen INC. | $38.72 | 2023 | Tukysa, Adcetris |
| Amgen INC. | $35.28 | 2023 | Lumakras |
| Celgene Corporation | $34.89 | 2023-2025 | Pomalyst, Opdivo |
| Janssen Biotech, INC. | $32.02 | 2025 | Rybrevant |
| Astellas Pharma US INC | $24.23 | 2024 | Padcev |
| Taiho Oncology, INC. | $23.90 | 2025 | |
| Deciphera Pharmaceuticals INC. | $22.96 | 2024 | Qinlock |
| Recordati_rare_diseases_inc. | $22.76 | 2023 | Panhematin |
| Kite Pharma, INC. | $22.50 | 2023 | |
| Pharmaessentia USA Corporation | $22.40 | 2025 | Besremi |
| Azurity Pharmaceuticals, INC. | $20.88 | 2025 | Danziten |
| Genentech USA, INC. | $18.06 | 2025 | Polivy |
| Array Biopharma INC | $14.73 | 2024 | Mektovi, Braftovi, Lorbrena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luann Harris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.